AIM: To investigate the activity and toxicity of irinotecan (CPT-11) as a single agent in patients with advanced gastric cancer after failure of previous 5-fluorouracil-based combination chemotherapy. PATIENTS AND METHODS: Sixteen patients with advanced gastric received CPT-11, 350 mg/m2 every 21 days. The median age of the patients was 54.6 years; ECOG performance status was 0-1 in 14 patients and 2 in 2 patients. Dominant metastatic sites included liver, lung, lymph nodes and peritoneum. RESULTS: No complete response was observed. Two patients (12.5%) achieved a partial response to treatment. One patient (6.25%) had a minor response. Ten patients (62.5%) had progressive disease on therapy, and 3 patients (18.75%) had stable disease. The median survival of all 16 patients was 5 months. Grade 3 neutropenia was observed in 3 patients (18.75%), grade 4 thrombocytopenia in 1 patient (6.25%), and grade 3 anemia in 1 patient (6.25%). Three patients (18.75%) suffered from grade 3 diarrhea. CONCLUSIONS: CPT-11 is moderately active and a well-tolerated regimen for selected advanced gastric cancer patients who experience disease progression after receiving first-line treatment.
AIM: To investigate the activity and toxicity of irinotecan (CPT-11) as a single agent in patients with advanced gastric cancer after failure of previous 5-fluorouracil-based combination chemotherapy. PATIENTS AND METHODS: Sixteen patients with advanced gastric received CPT-11, 350 mg/m2 every 21 days. The median age of the patients was 54.6 years; ECOG performance status was 0-1 in 14 patients and 2 in 2 patients. Dominant metastatic sites included liver, lung, lymph nodes and peritoneum. RESULTS: No complete response was observed. Two patients (12.5%) achieved a partial response to treatment. One patient (6.25%) had a minor response. Ten patients (62.5%) had progressive disease on therapy, and 3 patients (18.75%) had stable disease. The median survival of all 16 patients was 5 months. Grade 3 neutropenia was observed in 3 patients (18.75%), grade 4 thrombocytopenia in 1 patient (6.25%), and grade 3 anemia in 1 patient (6.25%). Three patients (18.75%) suffered from grade 3 diarrhea. CONCLUSIONS: CPT-11 is moderately active and a well-tolerated regimen for selected advanced gastric cancer patients who experience disease progression after receiving first-line treatment.
Authors: Harald Schmalenberg; Salah-Eddin Al-Batran; Claudia Pauligk; Thomas Zander; Alexander Reichart; Udo Lindig; Mathias Kleiß; Lothar Müller; Claus Bolling; Thomas Seufferlein; Peter Reichardt; Frank Kullmann; Henning Eschenburg; Alexander Schmittel; Matthias Egger; Andreas Block; Thorsten Oliver Goetze Journal: J Cancer Res Clin Oncol Date: 2017-12-28 Impact factor: 4.553
Authors: Kate Crawford; Erin Bontrager; Margaret A Schwarz; Apurva Chaturvedi; Daniel D Lee; Hassan Md Sazzad; Urs von Holzen; Changhua Zhang; Roderich E Schwarz; Niranjan Awasthi Journal: Cancer Biol Ther Date: 2021-12-09 Impact factor: 4.742
Authors: Keun-Wook Lee; Chi Hoon Maeng; Tae-You Kim; Dae Young Zang; Yeul Hong Kim; In Gyu Hwang; Sang Cheul Oh; Joo Seop Chung; Hong Suk Song; Jin Won Kim; Su Jin Jeong; Jae Yong Cho Journal: Oncologist Date: 2018-08-20